Horizon Pharma plc awarded Notice of Allowance in the US for VIMOVO (naproxen/esomeprazole) delayed release tablets.
M2 EQUITYBITES-March 31, 2017-Horizon Pharma plc awarded Notice of Allowance in the US for VIMOVO (naproxen/esomeprazole) delayed release tablets
(C)2017 M2 COMMUNICATIONS http://www.m2.com
Biopharmaceutical company Horizon Pharma plc (NasdaqGS:HZNP) announced on Thursday the receipt of a Notice of Allowance from the US Patent and Trademark Office (USPTO) for its US patent application entitled "Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs".
The Notice of Allowance for US patent application covers the US approved medicine VIMOVO (naproxen/esomeprazole) delayed release tablets.
According to the company, VIMOVO (naproxen/esomeprazole magnesium) is a fixed-dose combination of delayed-release enteric-coated naproxen, a non-steroidal anti-inflammatory drug (NSAID), and immediate-release esomeprazole magnesium, a stomach acid-reducing proton pump inhibitor (PPI), approved for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers.
This US patent application, which has been assigned the number 15/180,173, concludes the substantive examination of the patent application and will result in the issuance of a US patent upon completion of administrative processes. The term of the US patent scheduled to issue from this application will expire 31 May 2022.
Following issue, VIMOVO is expected to be listed in the US FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book, concluded the company.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Mar 31, 2017|
|Previous Article:||First Bancorp reminds shareholders of its acquired Carolina Bank of election deadline.|
|Next Article:||Tetraphase Pharmaceuticals announces TP-6076's selection under the CARB-X portfolio.|